Clearside Biomedical

FDA Alignment And Phase 3 Trials Will Advance AMD Therapy

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

09 Apr 25

Updated

16 Sep 25

Views

n/a

AnalystConsensusTarget's Fair Value

n/a

-93.2%

50.7%

-93.2%

50.7%

You can edit this narrative until Sep 17 10:15 AM. Then, changes will post as Updates.

Author's Valuation

US$6098.3% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates4

Shared on 16 Sep 25

Fair value Increased 1k%

Despite a significant increase in the consensus analyst price target from $4.00 to $60.00, analysts remain cautious due to Clearside's uncertain strategic direction, tough financing environment, and diminishing cash runway, which cloud visibility into the company's future. Analyst Commentary Announcement of exploring strategic alternatives created uncertainty around Clearside's future direction.

Shared on 01 May 25

Fair value Decreased 69%

Shared on 24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Increased 139%

AnalystConsensusTarget has increased revenue growth from 93.5% to 129.7%, increased future PE multiple from 104.5x to 148.3x and decreased shares outstanding growth rate from 0.0% to 0.0%.

AnalystConsensusTarget Fair Value

US$60

98.3% undervalued

Future estimation in

Growth p.a.

Decrease

Increase

Current revenue growth rate

63.54%

Pharma revenue growth rate

0.63%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

12.50%

Calculation

US$2.96m

Earnings '28

149.46x

PE Ratio '28

US$442.65m

Market Cap '28

US$442.65m

Market Cap '28

5.81m

No. shares '28

US$76.24

Share Price '28

US$76.24 Share Price '28

Discounted to 2025 @ 8.32% p.a.

US$60.00

Fair Value '25